"We appreciate the trust that GlaxoWellcome has demonstrated by selecting us to be their partner, and believe that this collaboration will greatly benefit both companies," stated Josef von Rickenbach, Parexel's chairman and CEO. "The purchase of this high quality fully operational clinical pharmacology unit enables us to expand the spectrum of services we provide to clients in the United Kingdom. It will also help us to address the needs of our clients based in the United States, Japan, and other countries, who have requested this type of service in the United Kingdom."
Parexel currently operates clinical pharmacology units in Washington, DC, Berlin, Germany, and Poitiers, France, which are a part of the Parexel Consulting Group (PCG) division.
Edited by Angelo DePalma
Managing Editor, Drug Discovery Online